Sorted By Test Name - Mayo Medical Laboratories

60483
FHPL
91178
HTLVL
83277
Human Papillomavirus (HPV), High-Risk DNA Detection Only, In
Situ DNA Hybridization
Clinical Information: Many human papillomavirus (HPV)-induced lesions are benign, presenting as
warts or condylomas. However, certain HPV types have been strongly associated with risk of
development of cervical, vaginal, and vulvar malignancy. These types are: 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, and 66.
Useful For: The detection of specific high-risk human papillomavirus DNA types (16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, and 66) in paraffin-embedded human tissue
Interpretation: Human papillomavirus (HPV) high-risk types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
and 66 are frequently found in cervical intraepithelial neoplasia (CIN) III (severe dysplasias and
carcinoma in situ) and cervical cancer. Recent studies have also shown that HPV high-risk types are
associated with a subset of oropharyngeal carcinomas. If additional interpretation or analysis is needed,
order #5439 Surgical Pathology Consultation along with this test.
Reference Values:
This test, when not accompanied by a pathology consultation request, will be answered as either positive
or negative.
If additional interpretation/analysis is needed, please request 5439 Surgical Pathology Consultation
along with this test.
Clinical References: 1. Singhi AD, Westra WH: Comparison of human papillomavirus in situ
hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head
and neck cancer based on a prospective clinical experience. Cancer 2010 May;2166-2173 2. Lorincz AT,
Lancaster WD, Kurman RJ, et al: Characterization of human papillomaviruses in cervical neoplasias and
their detection in routine clinical screening. Banbury Rep 1986; 21:225-237 3. Faulkner-Jones BE, Tabrizi
SN, Borg AJ, et al: Detection of human papillomavirus DNA and mRNA using synthetic, type-specific
oligonucleotide probes. J Virol Methods 1993;41:277-296
Human Placental Lactogen (HPL)
Reference Values:
Males and nonpregnant Woman: 0.00-0.10 mcg/mL
1st Trimester of Pregnancy: 0.20-2.10 mcg/mL
2nd Trimester of Pregnancy: 0.50-6.70 mcg/mL
3rd Trimester of Pregnancy: 4.50-12.80 mcg/mL
Test Performed by: Cambridge Biomedical Inc.
1320 Soldiers Field Road
Boston, MA 02135
Human T-Cell Lymphotropic Virus Types I and II (HTLV-I/-II)
Antibody Confirmation, Serum
Clinical Information: Human T-cell lymphotropic virus types I and II (HTLV-I and HTLV-II) are
closely related exogenous human retroviruses. HTLV-I was first isolated in 1980 from a patient with a
cutaneous T-cell lymphoma, while HTLV-II was identified from a patient with hairy cell leukemia in
1982. HTLV-I infection is endemic in southwestern Japan, Caribbean basin, Melanesia, and parts of
Africa, where HTLV-I seroprevalence rates are as high as 15% in the general population. In the United
States, the combined HTLV-I and HTLV-II seroprevalence rate is about 0.016% among voluntary blood
donors. About half of these infected blood donors are infected with HTLV-I, with most of them reporting
a history of birth in HTLV-I-endemic countries or sexual contact with persons from the Caribbean or
Japan. Smaller percentages report a history of either injection drug use or blood transfusion. Transmission
of HTLV-I occurs from mother to fetus, sexual contact, blood transfusion, and sharing of contaminated
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 981